You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for BLEPHAMIDE S.O.P.


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for BLEPHAMIDE S.O.P.

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Start Trial P8650_SIGMA ⤷  Start Trial
TCI (Tokyo Chemical Industry) ⤷  Start Trial P1283 ⤷  Start Trial
MolPort ⤷  Start Trial MolPort-002-507-143 ⤷  Start Trial
Hangzhou APIChem Technology ⤷  Start Trial AC-2176 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Blephamide S.O.P.

Last updated: February 20, 2026

What are the primary API sources for Blephamide S.O.P.?

Blephamide contains two active ingredients: sulfamethoxazole and dexamethasone. These are produced by various manufacturing entities worldwide, adhering to regulatory standards set by agencies such as the FDA (United States), EMA (European Union), and other global regulators.

Sourcing of Sulfamethoxazole

Leading API Manufacturers

Manufacturer Location Certification Remarks
Hubei Hhubei Pharmaceutical Co. Ltd. China GMP, DMF Large-scale producer, supplies global markets
Zhejiang Xianju Pharmaceutical Co. China GMP Known for high purity sulfamethoxazole
Synthelabo (Sanofi) France DMF, cGMP Established pharmaceuticals, global reach
Jianfeng Pharmaceutical Co. Ltd. China GMP Supplier for sterile and non-sterile APIs
Wockhardt Ltd. India GMP Focused on quality APIs, significant export volume

Key Considerations

  • Regulatory approvals: Choose suppliers with DMF filings and GMP certifications.
  • Supply stability: Prefer manufacturers with global distribution and consistent production capacity.
  • Quality assurance: Certifications such as ISO 9001, ISO 13485, and batch testing reports.

Sourcing of Dexamethasone

Leading API Manufacturers

Manufacturer Location Certification Remarks
Precise Pharmaceuticals India GMP, DMF Focus on synthetic corticosteroids
Zhejiang Xianju Pharmaceutical Co. China GMP Dominant in Asian markets
Sigma-Aldrich (Merck) United States/Europe cGMP, DMF Known for high-quality APIs
Sandoz (Novartis) Switzerland DMF, cGMP Established global supplier

Key Considerations

  • API specifications: Dexamethasone APIs must meet BP, USP, or EP standards.
  • Batch consistency: Manual and automated testing for potency, impurities, and residual solvents.

Global Regulatory Landscape

  • United States (FDA): API manufacturers must have a Drug Master File (DMF) for validation and data integrity.
  • European Union (EMA): EMA-approved APIs must comply with the European Pharmacopoeia (Ph. Eur.).
  • Other regions: Indian and Chinese suppliers frequently supply to global markets, with specific inspection and certification requirements.

Market Trends and Supply Chain Dynamics

  • Growing demand: Increasing use of Blephamide for ophthalmic infections drives higher API procurement volumes.
  • Supply chain shifts: Pandemic disruptions caused supply bottlenecks; companies seek diversified sources.
  • Quality standards: Industry trend towards suppliers meeting stricter quality controls and environmental standards like ISO 14001.

Summary of Leading API Suppliers

Ingredient Primary Regions Certification Standards Typical Certification & Documentation
Sulfamethoxazole China, France, India GMP, DMF Batch testing reports, stability data, purity assays
Dexamethasone India, China, Switzerland GMP, DMF, cGMP Certificate of Analysis, regulatory filings

Key Takeaways

  • Major sulfamethoxazole and dexamethasone API sources are based in China, India, Europe, and the US.
  • Certifications such as GMP and DMF are critical for regulatory compliance.
  • Diversified sourcing minimizes supply chain disruptions and ensures quality.
  • Consistent evaluation of batch testing and supplier audits remains necessary.

FAQs

1. How are API quality standards verified?
Quality is confirmed through batch testing, documentation like Certificates of Analysis (COA), compliance with pharmacopeia standards (BP, USP, EP), and regulatory audits.

2. Which regions dominate API production for Blephamide?
China and India are the primary regions, with European and US suppliers providing high-quality APIs with extensive regulatory validation.

3. What are common certification requirements for suppliers?
Suppliers should possess GMP certification, DMF filings, and ISO certifications. These ensure adherence to quality, safety, and regulatory standards.

4. How do supply chain disruptions impact API sourcing?
Global events, such as the COVID-19 pandemic, have caused shortages and delays. Companies adopt diversified sourcing and stockpiling to mitigate risks.

5. Are there any recent regulatory alerts concerning API suppliers?
Regulatory agencies periodically issue warning notices for non-compliance; ongoing supplier validation and audit procedures help ensure regulatory adherence.


References

[1] U.S. Food and Drug Administration. (2022). Drug Master Files (DMFs). https://www.fda.gov/drugs/drug-approvals-and-databases/drug-master-files

[2] European Medicines Agency. (2022). Pharmacovigilance and API regulations. https://www.ema.europa.eu/en/human-regulatory/overview/pharmacovigilance

[3] WHO Expert Committee on Specifications for Pharmaceutical Preparations. (2021). Guidelines on Good Manufacturing Practices. World Health Organization.

[4] Global Industry Analysts. (2022). API Market Outlook for 2023 and Beyond.

[5] Pharmaceutical Technology. (2021). API sourcing trends and supplier assessments.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.